Somatostatin Market

Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.

Somatostatin Market contains market size and forecasts of Somatostatin in global, including the following market information:

Global Somatostatin Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Somatostatin Market Sales, 2017-2022, 2023-2028, (K Pcs)

Global top five Somatostatin companies in 2021 (%)

The global Somatostatin market was valued at 346.3 million in 2021 and is projected to reach US$ 715 million by 2028, at a CAGR of 10.9% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

0.25mg/pcs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Somatostatin include Merck (Schweiz) AG, SANOFI-AVENTIS FRANCE, Lyomark Pharma GmbH, ALFA WASSERMANN S.p.A., Polypeptide Laboratories, Inc, SAMARTH, UBPL, HYBIO and TianTaiShan, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Somatostatin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Somatostatin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Somatostatin Market Segment Percentages, by Type, 2021 (%)

• 0.25mg/pcs
• 0.75mg/pcs
• 3mg/pcs

Global Somatostatin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Somatostatin Market Segment Percentages, by Application, 2021 (%)

• Hormonal Disorder
• Oncology
• Metabolic Disorder
• Others

Global Somatostatin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)

Global Somatostatin Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Somatostatin revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Somatostatin revenues share in global market, 2021 (%)
• Key companies Somatostatin sales in global market, 2017-2022 (Estimated), (K Pcs)
• Key companies Somatostatin sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Merck (Schweiz) AG
• SANOFI-AVENTIS FRANCE
• Lyomark Pharma GmbH
• ALFA WASSERMANN S.p.A.
• Polypeptide Laboratories, Inc
• SAMARTH
• UBPL
• HYBIO
• TianTaiShan
• Yangtze River
• Siyao
• Shuangcheng
• Hainan Zhonghe
• SL PHARM
• Wuhan Hualong
• Qingdao Guoda
• Chengdu Shengnuo
• Longjin